Resources

TEXTME

Preventing cardiovascular disease through a simple text message

The World Health Organization states that cardiovascular disease (CVD) has been the number one global cause of death; with an estimation of 17.5 million people dying from CVD in 20121, representing 31% of all global deaths. CVD has been and is currently the major cause of death in Australia2 accounting for over 43,600 deaths in […]

Read More

December 23rd, 2016

Steadying confidence for clinical trials in India

For over 30 years, India has been conducting global clinical trials. With over 500 sites and over a billion people, India was a key destination for clinical trials for its vast treatment naïve clinical population. However, the environment has fluctuated throughout recent years, as The Central Drugs Standard Control Organization (CDSCO), India’s regulatory agency for […]

Read More

December 21st, 2016
SMARTHealth

SMARTHealth – A study on e-health in rural communities

Health systems in low and middle income countries continue to face considerable challenges in providing high-quality, affordable and universally accessible care – this is primarily evident in rural areas. As of 2014, approximately 876.1 million people live in rural areas within India with poor access to primary healthcare. This amounts to more than two-thirds of […]

Read More

December 19th, 2016
Research confirms link between birthweight and cancer

Research confirms link between birthweight and cancer

New research from the International Childhood Cancer Cohort Consortium (I4C) confirms that childhood cancer is linked to birthweight. The incidence of childhood cancer appears to be slowly rising, at a rate of approximately 1% per year in developed countries. Link between birthweight and cancer Risk rose by 26 percent for every kilogram increase in birthweight for […]

Read More

December 17th, 2016
Regulatory environment in China

China’s dynamism requires a nimble CRO with extensive research networks

China’s meteoric growth over the past twenty years (or so) has seen it go from strength to strength, particularly in the clinical trials sector. As the clinical trial market of the world’s most populous nation (and second largest economy) continues to mature, so does their regulatory requirements. These regulatory adjustments pose a risk to sponsors […]

Read More

December 15th, 2016
Recruitment in a CRT stroke trial

Recruitment in a Cluster Randomized Stroke Trial

Generally, the unit of randomization in a randomized clinical trial (RCT) is the individual participant (the patient). Occasionally, the unit of randomization can be a cluster, such as hospitals, schools, villages, etc. When randomizing large groups, the concept of cluster randomized trials (CRTs) has become increasingly common. Patient clusters are allocated to the intervention arms […]

Read More

December 13th, 2016
Real time access to data

Clinical Trial Performance is Improving with Real Time Access to Data Intro

Over the years, technology within medical research has advance enormously, improving its methods of inputting and capturing data. When conducting clinical trials, it is crucial that current data is available throughout the study so that informed decisions can be made from start to finish. Electronic data capture (EDC) systems manage digital data from various channels […]

Read More

December 11th, 2016
Pragmatic approach to cluster randomized trials

Pragmatic approach to cluster randomized trials – a perspective from HeadPost

Cluster randomized trials (CRTs) is the concept of grouping individuals for randomization into a treatment or control group. The design is increasingly becoming more common when randomizing large groups. It also reduces bias as there are less decision making required from clinicians or nurses. A study to compare the effects of a patients head position […]

Read More

December 9th, 2016
Part III China

Part III: China’s Future in Global Clinical Research

Active international collaboration has facilitated the rise of the Asia-Pacific region in global clinical research. In the first two parts of this blog series, we’ve discussed how Japan and South Korea – whose clinical research environments vary significantly from each other – share many common interests in their pursuit for advancing clinical R&D. The open […]

Read More

December 7th, 2016
Part II Insights on CT environment – Sth Korea

Part II: Insights on the Clinical Trial Landscape of South Korea

Japan has taken significant steps in establishing itself as a major player in the global clinical research community, driving the demand for more clinical trials across East Asia as a result. By officially acknowledging and seeking clinical data from the Asia-Pacific region, Japan is facilitating a dialogue with one of the most powerful and capable […]

Read More

December 5th, 2016